Tiny trial tracks new Drug's journey in dialysis patients
NCT ID NCT07284043
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This early-stage study looks at how the experimental drug MT1013 moves through and leaves the body of people on hemodialysis who have secondary hyperparathyroidism. Six participants will receive a single dose, and researchers will measure radioactivity in blood, urine, and stool to track the drug. The goal is not to treat the disease but to understand the drug's breakdown and elimination, which is a necessary step before larger safety and effectiveness trials can begin.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMODIALYSIS SUBJECTS WITH SECONDARY HYPERPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
RECRUITINGJinan, Shandong, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MT1013 (a dual-target agonist drug)
What this could lead to
If successful, this study will clarify how MT1013 is absorbed and eliminated, which is essential for future dosing and safety studies.
What could go wrong
This is a very early Phase 1 trial with only 6 participants, so results may not apply broadly. The drug is still experimental and may not prove effective or safe in larger trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.